It has been demonstrated also that therapeutic strategies targeting EZH2 or its downstream targets, such as the ciliary-related oncogene PLK1, in combination with BRAF inhibitors are potential novel therapeutic options in melanomas with BRAF mutations [138]. Here, EZH2 is linked to melanoma.